Restructurings & Charges

Luminar Technologies, Inc./DE announced a restructuring with charges of approximately $2.0 million to $3.0 million in cash charges (approximately 25%).

“On October 29, 2025, the Company committed to a plan to reduce its workforce by approximately 25% in order to reduce operating costs. The reduction will commence immediately and is expected to be substantially completed by 2025 year-end. The Company estimates that it will incur approximately $2.0 million to $3.0 million in cash charges associated with employee severance and related employee costs, to be incurred primarily in the fourth quarter of 2025.”

COLGATE PALMOLIVE CO announced a restructuring with charges of $200 and $300 million affecting North America, Latin America, Europe, Asia Pacific, Africa/Eurasia, Hill's Pet Nutrition, Corporate.

“the Company’s Board of Directors approved a new three-year productivity program to drive future growth and support the Company’s 2030 strategy (the “Strategic Growth and Productivity Program”). The program includes initiatives to better align the Company’s organizational structure to support its strategic initiatives, optimize the Company’s global supply chain to drive agility and efficiencies and simplify and streamline its organizational structure to reduce overhead costs. The Strategic Growth and Productivity Program is estimated to result in cumulative pre-tax charges, once all initiatives are approved and implemented, totaling between $200 and $300 million”

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $25 to $28 million affecting enterprise-wide.

“The Company expects pre-tax cash and non-cash asset charges of approximately $25 to $28 million resulting from the termination of certain contracts.”

Indivior Pharmaceuticals, Inc. announced a impairment with charges of approximately $21 to $27 million affecting enterprise-wide.

“The Company expects pre-tax cash and non-cash asset charges of approximately $21 to $27 million resulting from the write-downs of intangible assets and inventory.”

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $15 to $21 million affecting real estate.

“The Company expects pre-tax cash and non-cash asset charges of approximately $15 to $21 million resulting from the consolidation and exit of certain real estate properties, including write-downs of leasehold improvements, fixed assets, and acceleration of leased property restoration costs.”

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $33 to $37 million affecting enterprise-wide.

“The Company expects pre-tax employee severance and related employee exit charges of approximately $33 to $37 million, of which $17 million was recognized in the third quarter of 2025.”

Celanese Corp announced a restructuring with charges of approximately $70 – 90 million affecting facility in Lanaken, Belgium (acetate tow production site) (approximately 160 employees).

“the completion of such consultation process. As a result of this intended closure, the Company expects to record expenses, excluding employee termination costs, of approximately $70 – 90 million, consisting primarily of approximately $55 – 65 million of non-cash accelerated depreciation of fixed asset costs and approximately $15 – 25 million of other”

Sensata Technologies Holding plc announced a impairment with charges of approximately $33 million of charges primarily related to excess capacity affecting electrification products and operations.

“approximately $33 million of charges primarily related to excess capacity related to electrification products and operations”

Sensata Technologies Holding plc announced a impairment with charges of approximately $226 million of non-cash impairment charges affecting goodwill associated with the Company’s Dynapower reporting unit.

“These charges include approximately $226 million of non-cash impairment charges related to the goodwill associated with the Company’s Dynapower reporting unit”

Sensata Technologies Holding plc announced a impairment with charges of approximately $259 million affecting Company’s Dynapower reporting unit.

“On October 28, 2025, in connection with the preparation of the Company’s financial statements for the quarter ended September 30, 2025, the Company concluded that charges totaling approximately $259 million were required to be recorded in the third quarter of 2025.”

CARTERS INC announced a restructuring with charges of approximately $10.1 million to $11.1 million in charges, of which $6.1 million in charges were recorded in the third quarter of fiscal 2025, and approximately $.

“On September 16, 2025, the Board of Directors of Carter’s, Inc. (the “ Company ”) approved an organizational restructuring plan (the “ Plan ”) to right-size the Company's cost structure and improve future profitability.”

CHEGG, INC announced a restructuring with charges of approximately $15 million to $19 million (approximately 388 employees, or about 45% of our current workforce).

“align our cost structure with our newly announced strategic focus relating to our operations on a stand-alone basis. We estimate that we will incur charges of approximately $15 million to $19 million in connection with these actions, primarily consisting of expenditures for employee transition and severance payments, employee benefits and other related costs.”

ALBEMARLE CORP announced a impairment affecting Eurecat joint venture.

“Item 2.06 Material Impairments. In connection with the transactions described under Item 1.01 and”

UNIVERSAL LOGISTICS HOLDINGS, INC. announced a impairment affecting intermodal segment.

“On October 21, 2025, the Audit Committee of the Board of Directors of Universal Logistics Holdings, Inc. (the “Company”) concluded that the Company will record a material non-cash impairment charge related to certain intangible assets associated with the Company’s intermodal segment in connection with the preparation of its financial statements for the third quarter ended September 27, 2025.”

APPLIED MATERIALS INC /DE announced a restructuring with charges of approximately $160 million to $180 million (approximately four percent of its global workforce).

“On October 23, 2025, Applied Materials, Inc. (“Applied” or the “Company”) approved a workforce reduction plan to position the Company for continued growth as a more competitive and productive organization. Applied expects approximately four percent of its global workforce to be impacted under this action and the Company to incur charges of approximately $160 million to $180 million, consisting primarily of severance and other one-time employment termination benefits to be paid in cash, and other non-cash related charges.”

NOVAVAX INC announced a impairment with charges of $29 million.

“the Company expects to recognize a non-cash charge of $29 million during the third quarter of 2025 associated with the extinguishment of the 5.00% Convertible Senior Notes due 2027 and announced on August 27, 2025.”

NOVAVAX INC announced a impairment with charges of between $96 million and $98 million affecting 700 Quince Orchard Road, Gaithersburg, MD facility.

“on October 17, 2025, the Company concluded that it expects to recognize an estimated non-cash impairment charge of between $96 million and $98 million in the third quarter of 2025, which includes the write off of the right-of-use asset, property and equipment, and intangibles, partially offset by a gain recognized on the sale of adjacent land under the Parcel Agreement.”

Alector, Inc. announced a restructuring with charges of approximately $7.7 million affecting across the organization (approximately 75 employees).

“The Company initiated a reduction in force impacting approximately 75 employees across the organization. Total incremental restructuring charges associated with the reduction in force are expected to be approximately $7.7 million.”

KALA BIO, Inc. announced a restructuring affecting Company's remaining assets (terminated all remaining employees not deemed necessary by Oxford to execute a foreclosure of the Company’s assets).

“On October 19, 2025, the Board terminated all remaining employees not deemed necessary by Oxford to execute a foreclosure of the Company’s assets (the “Reduction”).”

MOLSON COORS BEVERAGE CO announced a restructuring with charges of in the range of $35 million to $50 million affecting Americas business (approximately 400 salaried positions).

“with the corporate restructuring, the Company currently expects to incur certain restructuring charges, which are expected to be primarily cash charges, in the range of $35 million to $50 million. Substantially all of the charges are expected to be related to severance payments and post-employment benefits to be incurred in the fourth quarter of 2025. Of”

BROADWAY FINANCIAL CORP \DE\ announced a impairment with charges of $25.9 million goodwill impairment charge.

“On October 15, 2025, the Audit Committee of the Board of Directors of Broadway Financial Corporation (the “Company”) (NASDAQ: BYFC), the holding company of City First Bank, National Association, concluded that, based on its annual impairment analysis, the Company’s goodwill is impaired in accordance with U.S. GAAP. Consequently, the Company expects to record a non-cash $25.9 million goodwill impairment charge for the quarter ended September 30, 2025.”

AMPCO PITTSBURGH CORP announced a impairment with charges of ranging between $43 to $45 million affecting UES-UK (Union Electric Steel UK Limited).

“Ampco-Pittsburgh would expect to recognize a non-cash impairment charge in the fourth quarter of 2025 ranging between $43 to $45 million, based on estimates as of September 30, 2025.”

General Motors Co announced a impairment with charges of $1.6 billion affecting GM North America (GMNA).

“On October 7, 2025, the Audit Committee of the Company’s Board of Directors approved charges of $1.6 billion in GM North America (GMNA) in the three months ended September 30, 2025, based on a planned strategic realignment of our EV capacity and manufacturing footprint to consumer demand.”

Polaris Inc. announced a impairment with charges of approximately $275 million to $325 million, or approximately $230 million to $280 million net of an expected tax benefit of approximately $45 million affecting Indian Motorcycle Business.

“On October 10, 2025, certain wholly owned subsidiaries of the Company entered into a definitive agreement to sell the Indian Motorcycle Business. Under U.S. generally accepted accounting principles, the Indian Motorcycle Business will be classified as held for sale. Accordingly, the Company will be required to record the assets related to the Indian Motorcycle Business at fair value, less an amount of estimated transaction costs. Further, the Company recorded related impairment charges in the third quarter of 2025. The Company currently expects estimated pre-tax charges of approximately $275 million to $325 million, or approximately $230 million to $280 million net of an expected tax benefit of approximately $45 million.”

PETMED EXPRESS INC announced a impairment with charges of $1.2 million affecting PCRX trade name.

“On October 1, 2025, the Audit Committee of the Board of Directors (the “Audit Committee”) of PetMed Express, Inc. (the “Company”), upon the recommendation of the Company’s management, concluded that a $1.2 million non-cash impairment of the Company’s PCRX trade name is required to be recorded in the quarter ended March 31, 2025.”

Atara Biotherapeutics, Inc. announced a restructuring with charges of $1.3 million (approximately 29% of its current employees).

“to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by January 2026. The Company expects to recognize approximately $1.3 million for severance and related benefits for employees laid off under the reduction in force. Approximately fifty percent of these charges are salary continuation payments and wages”

ZYNEX INC announced a impairment with charges of pre-tax non-cash asset impairment charges up to approximately $31.0 million primarily related to the impairment of goodwill and other assets associated with the affecting ZMS.

“pre-tax non-cash asset impairment charges up to approximately $31.0 million primarily related to the impairment of goodwill and other assets associated with the ZMS business.”

ZYNEX INC announced a restructuring with charges of pre-tax cash charges of approximately $0.1 million associated with severance payments to former ZMS employees affecting ZMS (terminated the positions of a majority of ZMS employees).

“cost savings expected from the reduction in force. ​ As a result of the actions described above, the Company expects to incur (i) pre-tax cash charges of approximately $0.1 million associated with severance payments to former ZMS employees and (ii) pre-tax non-cash asset impairment charges up to approximately $31.0 million primarily related to the”

Trinseo PLC announced a restructuring with charges of $80 million to $100 million affecting MMA production operations in Rho, Italy and ACH production operations in Porto Marghera, Italy.

“assets. Moving forward, the company will source all MMA feedstock from third-party producers. ​ The Company expects to record total pre-tax restructuring charges of $80 million to $100 million, principally comprised of $3 million to $6 million of employee-related costs, $40 million to $46 million of asset-related charges and $37 million to $48 million”

BNB PLUS CORP. announced a restructuring with charges of $1.4 million aggregate pre-tax charges for severance payments, employee benefits, and related costs affecting workforce reduction, reduction of 16 employees (approx. 60%) (reduction of the Company’s current workforce by sixteen employees, or approximately 60%).

“On September 30, 2025, the Board of Directors of Applied DNA Sciences, Inc. (the “ Company ”) authorized, and its officers implemented, a restructuring plan pursuant to which the Company will reduce overall operating expenses to focus resources on its previously announced BNB-focused treasury strategy. The restructuring plan includes a reduction of the Company’s current workforce by sixteen employees, or approximately 60%. The Company estimates that it will incur aggregate pre-tax charges of approximately $1.4 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”

Atkore Inc. announced a restructuring with charges of pre-tax cash charges of between $5 and $15 million, which consist of employee-related costs and other cash shutdown costs affecting three facilities (employee-related costs).

“these facilities by approximately the end of the second quarter of fiscal 2026. As a result of the foregoing plan, the Company expects to incur pre-tax cash charges of between $5 and $15 million, which consist of employee-related costs and other cash shutdown costs. The Company anticipates that the majority of these costs will be incurred by the end of the”

KALA BIO, Inc. announced a restructuring with charges of approximately $0.4 million affecting KPI-012 and its mesenchymal stem cell secretome platform (approximately 19 employees, or approximately 51%).

“generally accepted accounting principles as a result of the Reduction. Subsequent to the Original Report, the Company determined that it expects to incur costs of approximately $0.4 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. The costs related to the Reduction are expected to be substantially incurred in”

Bolt Biotherapeutics, Inc. announced a restructuring with charges of between approximately $1.5 million to $2.0 million affecting the Company (approximately 20 employees, or approximately 50% of the Company’s workforce).

“On October 1, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), implemented a restructuring plan pursuant to which it will reduce overall operating expenses to preserve cash. The restructuring plan includes a reduction of the Company’s current workforce by approximately 20 employees, or approximately 50% of the Company’s workforce. The Company estimates that it will incur aggregate pre-tax charges between approximately $1.5 million to $2.0 million in connection with the reduction-in-force, primarily consisting of severance payments, employee benefits, and related costs.”

Cardlytics, Inc. announced a restructuring with charges of approximately $2.3 million (approximately 90 full-time employees).

“On October 1, 2025, Cardlytics, Inc. (the “Company”) committed to a plan to reduce its workforce by approximately 90 full-time employees, representing approximately 24% of the Company’s current workforce (the “Plan”). The Plan is intended to optimize the Company’s cost structure and is part of a broader cost-reduction initiative that also includes measures beyond full-time employee reductions. The Company estimates that it will incur non-recurring charges of approximately $2.3 million in connection with the workforce reduction under the Plan, consisting of severance payments and related costs.”

Theriva Biologics, Inc. announced a restructuring with charges of approximately $520,000 affecting global Company workforce (approximately seven employees or 32% of the current global Company workforce).

“its best opportunity for success. The Company expects to substantially complete the employee reduction immediately and estimates that it will incur a total of approximately $520,000 in charges in connection with the workforce reduction, all of which is expected to be incurred in the fourth quarter of 2025. These charges consist primarily of cash severance and”

GENERAL MILLS INC announced a restructuring with charges of approximately $82 million of restructuring charges affecting North America Foodservice pizza crust manufacturing facility in St. Charles, Missouri; two North America Pet manufacturing facilities in Joplin, Missouri; consolidation of assets at certain other faci.

“On September 25, 2025, General Mills, Inc. approved a multi-year organizational initiative to increase the competitiveness of our supply chain. To consolidate capacity, improve our cost structure, and support this initiative, we approved (i) the closure of our North America Foodservice pizza crust manufacturing facility in St. Charles, Missouri, (ii) the closure of two of our North America Pet manufacturing facilities in Joplin, Missouri that we acquired in the Whitebridge Pet Brands acquisition, and (iii) the consolidation of assets at certain of our other facilities, pursuant to which we expect to incur approximately $82 million of restructuring charges, of which approximately $17 million will be cash.”

Alcoa Corp announced a restructuring with charges of approximately $890 million ($623 million (after-tax), or $2.41 per share) affecting Kwinana alumina refinery located in Western Australia (approximately 220 employees).

“In the third quarter of 2025, the Company will record total restructuring and related charges of approximately $890 million ($623 million (after-tax), or $2.41 per share) related to the permanent closure of the Refinery, including approximately $375 million of non-cash impairment charges.”

SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $4.1million to $4.3 million (approximately one-third).

“As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million”

KALA BIO, Inc. announced a restructuring affecting the Company's workforce (approximately 19 employees, or approximately 51%).

“On September 28, 2025, the board of directors (the “Board”) of KALA BIO, Inc. (the “Company”) determined to cease development of KPI-012 and its mesenchymal stem cell secretome platform and to take steps to preserve cash as the Company explores its strategic options. In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).”

IO Biotech, Inc. announced a restructuring with charges of approximately $1.0 million to $1.5 million (approximately 50% of the Company’s workforce globally).

“On September 25, 2025, the Board of Directors of IO Biotech, Inc. (the “Company”) approved a restructuring and workforce reduction plan (the “Plan”) to conserve capital to align the Company’s operations with its primary focus of advancing development of Cylembio ® (imsapepimut and etimupepimut, adjuvanted). The Plan is expected to result in a reduction of approximately 50% of the Company’s workforce globally. In connection with the implementation of the Plan, the Company expects to incur one-time charges and cash expenditures in a range of approximately $1.0 million to $1.5 million, primarily related to employee wages and severance payments, healthcare continuation, earned vacation time and related termination costs.”

STARBUCKS CORP announced a restructuring with charges of approximately $1 billion affecting North America business.

“organization. The Company expects that a majority of the store closures will be completed by the end of this fiscal year. The Company estimates that it will incur approximately $1 billion related to the store closures, support organization transformation, and other restructuring activities, with 90% of the expenses attributable to the North America business. The”

SPRUCE POWER HOLDING CORP announced a restructuring with charges of approximately $1 million (approximately 40 employees and contractors, representing approximately 19% of the Company’s workforce).

“who were informed of the reduction in force on September 24, 2025. In connection with the reduction in force, the Company estimates that it will incur charges of approximately $1 million, consisting primarily of cash expenditures for employee severance and related costs. The Company expects to recognize the majority of these charges in the third quarter of 2025.”

CITIGROUP INC announced a impairment.

“Item 2.06 Material Impairments”

MAXCYTE, INC. announced a restructuring with charges of approximately $2.9 million affecting global workforce (approximately 34% of the Company’s workforce globally).

“On September 22, 2025, the Board of Directors of MaxCyte, Inc. approved a workforce reduction plan (the “Plan”) as part of the Company’s ongoing efforts to streamline operations, improve its cost structure, and align resources with strategic priorities. The Plan is expected to result in a reduction of approximately 34% of the Company’s workforce globally, which includes both directly employed personnel and individuals engaged through third-party employer-of-record (“EOR”) arrangements. ​ In connection with the implementation of the Plan, the Company currently estimates that it will incur an aggregate of approximately $2.9 million of pre-tax, cash charges.”

STANDARD BIOTOOLS INC. announced a restructuring with charges of approximately $7.5 million (approximately 15% of its total global workforce).

“The Company currently expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be approximately $7.5 million. These estimates are subject to a number of assumptions, and actual results may differ. The Company may also incur additional costs not currently contemplated due to events that”

X4 Pharmaceuticals, Inc announced a restructuring with charges of approximately $3.3 million for severance and other employee termination-related costs affecting the Company (reduce its workforce by approximately 50%).

“On September 17, 2025, X4 Pharmaceuticals, Inc. (the “Company” or “X4”) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long‐term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia. As part of this initiative, the Company will reduce its workforce by approximately 50%, a step anticipated to result in annualized cost savings of approximately $13 million. The Company estimates that the workforce reduction will be substantially completed in the third quarter of 2025. The Company estimates that it will incur cash charges of approximately $3.3 million for severance and other employee termination-related costs.”

Optimus Healthcare Services, Inc. announced a restructuring (a reduction in force).

“the Board approved certain wind down initiatives, including a reduction in force.”

First Internet Bancorp announced a impairment with charges of approximately $33.5 million affecting single-tenant lease financing loans portfolio.

“First Internet Bancorp (the “Company”) estimates that it will recognize an after-tax charge in the quarter ending September, 30, 2025 of approximately $33.5 million, representing difference between the sale price of the Portfolio and its book value upon transfer to held for sale status and the subsequent Sale.”

Asana, Inc. announced a impairment with charges of approximately $29 million to $32 million affecting leased headquarters office space in San Francisco, California.

“On September 5, 2025, the Company's management concluded that the Sublease will result in impairment expenses of approximately $29 million to $32 million in the period ending October 31, 2025.”

FIFTH THIRD BANCORP announced a impairment with charges of in the range of $170 million to $200 million affecting asset-backed finance loan.

“the Bancorp concluded that a material charge for impairment would result from this alleged external fraudulent activity. The outstanding balance on this loan is approximately $200 million. Based on currently available information, the Bancorp currently estimates that the non-cash impairment charge associated with this asset-backed finance loan, which would be”